Home / Tools / Cell lines / Cyclin B1-Venus Reporter Cell Line [RPE1 cycB1-venus/+ KI clone 20G11]
Cyclin B1-Venus Reporter Cell Line [RPE1 cycB1-venus/+ KI clone 20G11]
Contributors
Inventor
Institute
Jonathon Pines
University of Cambridge
SKU:
153464
Product description:
Somatic knock-in reporter cell with endogenous expression of cyclin B1 fused to the yellow fluorescent protein Venus (cyclin B1-Venus fusion protein). Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This Cyclin B1 cell line functions as a cell cycle reporter across the G2/mitotic-specific phase of the cell cycle. See also the Mad2 and Cyclin A2 versions of these cell lines for a broader analysis of the different phases of the cell cycle. This cell line is an endogenous reporter for cyclin B1 levels and activity.
Alternate name:
CCNB1
Conditional:
Yes
Production details:
To generate the cell line recombinant adenovirus-associated virus (rAAV)-mediated gene targeting was used to fuse the open reading frame (ORF) of yellow fluorescent protein (Venus) with exon 9 of the CCNB1 (Cyclin B1) gene in hTert-RPE1 cells (RPE1; retinal pigment epithelial). RPE1 cells were chosen because they have a normal diploid karyotype, are not transformed and exhibit little cell death when arrested in mitosis; tagging the endogenous Cyclin B1 protein in RPE1 cells avoided the compl…
Parental cell line:
RPE1
Cat. #:
153464
Provenance and Ownership:
The Cyclin B1-Venus Reporter Cell Line [RPE1 cycB1-venus/+ KI clone 20G11] is owned by Cancer Research UK. CancerTools supplies the Cyclin B1-Venus Reporter Cell Line [RPE1 cycB1-venus/+ KI clone 20G11] under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Cyclin B1-Venus Reporter Cell Line [RPE1 cycB1-venus/+ KI clone 20G11] directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements.
Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.